Pipeline
Biomilq Labs is advancing programs in infection, neonatal care, oncology, immunoglobulin platform development, elder care, and intestinal dysbiosis. The pipeline is centered on clinical settings where current care still leaves meaningful unmet needs.
Areas of Need
The portfolio is organized around settings where disease burden remains high and patient populations may be medically vulnerable, clinically complex, or difficult to treat.
Serious infection burden
Healthcare-associated infection continues to affect hospitalized patients, and neonatal sepsis remains a major contributor to newborn mortality worldwide. BQ-Skin and BQ-Neonate are positioned around prevention-oriented needs in vulnerable care settings.
Cancer and durable clinical performance
Cancer drug resistance remains a major cause of treatment failure, and durable clinical performance remains important across advanced therapeutic programs. BQ-Tumor and BQ-IGVivo are aligned with those persistent translational needs.
Aging and gut resilience
Advancing age increases fracture risk and physiologic vulnerability, while microbiome imbalance can contribute to inflammation and disease susceptibility. BQ-Elder and BQ-Belly are positioned around patient populations where supportive therapeutic development may have broad relevance.
Programs
Each program is framed at a high level around its target clinical setting. Public descriptions are intentionally focused on indication and patient need rather than technical development details.
Hospital-acquired skin infection prevention
A program focused on prevention and treatment of hospital-acquired skin infection.
Scientific note. Hospital-acquired infection remains common, costly, and clinically serious, and Staphylococcus aureus remains an important pathogen in hospital settings.
Potential relevance. A successful prevention-oriented skin therapeutic could help address infection risk in acute-care environments.
Sepsis prevention in neonates
A program focused on prevention of sepsis in neonates.
Scientific note. Neonatal sepsis remains a major cause of newborn mortality and demands rapid intervention in highly vulnerable patients.
Potential relevance. A preventive neonatal sepsis program could have important relevance in newborn and intensive-care settings.
Anti-tumor development
A program focused on anti-tumor therapeutic development.
Scientific note. Cancer remains difficult to control when resistance, recurrence, or treatment tolerability limit durable response.
Potential relevance. New anti-tumor options may matter most where longer control or better tolerability could change clinical outcomes.
Immunoglobulin potency and longevity in vivo
An immunoglobulin platform focused on improved in vivo potency and longevity.
Scientific note. For immunoglobulin programs, potency and persistence remain central to meaningful clinical performance.
Potential relevance. Improved in vivo potency and longevity could support more durable exposure and potentially lower dosing burden.
Elder care therapeutic development
An elder care therapeutic program with intended benefits for bone health and host resilience.
Scientific note. Older adults face rising fracture risk, age-related bone fragility, and broader physiologic vulnerability.
Potential relevance. Programs that support bone health and resilience may have broad relevance across medically complex older populations.
Intestinal dysbiosis therapeutic development
A program focused on intestinal dysbiosis as a therapeutic target.
Scientific note. The gut microbiome contributes to host defense, immune development, and metabolic function, and microbiome imbalance can contribute to disease susceptibility.
Potential relevance. Therapeutic programs targeting intestinal dysbiosis may matter where gut instability contributes to ongoing disease burden.